A Phase 2 Open-Label Treatment Development Study of MDMA-Assisted Cognitive Processing Therapy (CPT) for Posttraumatic Stress Disorder (PTSD)

NCT05067244 | Completed Phase 2 FDA Drug

• 1 other identifier: 2020-087
• Study Type: interventional
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

This study is designed to provide information on whether the drug MDMA, combined with Cognitive Processing Therapy (CPT), is safe and helpful for people with Post Traumatic Stress Disorder (PTSD). PTSD is a serious debilitating disorder that negatively impacts a person's daily life, and can result in diminished functioning, fractured relationships, inability to maintain employment, substance abuse, depression, and suicide risk. People who suffer from PTSD relive their traumatic experience(s) through nightmares and flashbacks, have difficulty sleeping, and feel detached or estranged. CPT is a manualized treatment for PTSD, which has the participant make meaning of the traumatic event and its impact on their life. CPT is one of the treatments with the best evidence for the treatment of PTSD to date. Clients with PTSD discuss how they believe the trauma has impacted them, and the therapist teaches the client skills to challenge areas where they are "stuck" remembering the traumatic event. MDMA is a drug commonly used recreationally that has been increasingly studied because of its ability to reduce the impact of PTSD symptoms. The effects of MDMA are reduced fear, enhanced communication, trust and introspection, and increased empathy and compassion. The effects of MDMA create a state that enhances the positive effects of therapy by increasing the ability to tolerate negative emotions and allowing clients to stay engaged in therapy without being overwhelmed by the intense emotions surrounding the memories of traumatic events. It is believed that MDMA may help promote the effects of CPT. Given the properties of MDMA, specifically in inducing the ability to stay with emotion and challenging cognitions, these effects are especially relevant to the mechanisms of CPT. This is a pilot study exploring CPT integrated with MDMA-assisted psychotherapy for treatment of PTSD. This study will enroll 10 participants diagnosed with PTSD, who will undergo a 2-month course of psychotherapy that includes CPT integrated with MDMA-assisted psychotherapy. Participants will go through CPT sessions, and two doses of MDMA will be used as an adjunct to psychotherapy. Since this is the first time that CPT is being combined with individual MDMA-assisted psychotherapy for PTSD, the researchers are interested in gathering preliminary information about the blending of these two therapeutic approaches.

Conditions

Post Traumatic Stress Disorder

Keywords

MDMA; Cognitive Processing Therapy (CPT)

Outcome Measures

Primary Outcomes (4)

• Change From Baseline to Primary Endpoint in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Score

  The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

  Baseline (enrolment) to endpoint (6 month follow up)

• Change From Baseline to Midpoint (visit 6) in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Score

  The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

  Baseline (enrolment) to midpoint (visit 6, 3-4 weeks)

• Change From Baseline to 1 Month Follow up in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Score

  The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

  Baseline (enrolment) to 1 month follow up

• Change From Baseline to 3 Month Follow up in Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) Score

  The Clinician-Administered PTSD Scale for DSM-5 (CAPS-5) is a clinician administered and scored assessment of PTSD symptoms via structured interview based upon PTSD diagnosis in DSM-5. It contains symptom subscales, a total severity score, and a diagnostic score. The total severity score is a sum of symptom frequency and intensity scores for the subscales B (re-experiencing), C (avoidance) and D (hypervigilance) and ranges from 0 to 136, with higher scores indicating greater severity of PTSD symptoms.

  Baseline (enrolment) to 3 month follow up

Secondary Outcomes (8)

• Change From Baseline to Endpoint in PTSD Symptoms Checklist

  Baseline (enrolment) to endpoint (6 month follow up)

• Change From Baseline to Midpoint (Visit 6) in PTSD Symptoms Checklist

  Baseline (enrolment) to midpoint (visit 6, 3-4 weeks)

• Change From Baseline to 1 Month Follow up in PTSD Symptoms Checklist

  Baseline (enrolment) to 1 month follow up

• Change From Baseline to 3 Month Follow up in PTSD Symptoms Checklist

  Baseline (enrolment) to 3 month follow up

• Change From Baseline to Endpoint in The Patient Health Questionnaire-9 Depression Symptoms

  Baseline (enrolment) to endpoint (6 month follow up)

Study Arms (1)

MDMA assisted psychotherapy

EXPERIMENTAL

Participants will undergo a 2-month course of CPT psychotherapy for PTSD with two sessions that integrate MDMA-assisted psychotherapy. MDMA will be administered ini two separate sessions and integrated into the psychotherapy protocol. The two doses of MDMA during this study will be used as an adjunct to psychotherapy.

Drug: MDMA

Interventions

MDMA DRUG

MDMA assisted psychotherapy

MDMA assisted psychotherapy

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Meet criteria for PTSD
• Are at least 18 years old
• Are a resident of Ontario and live within 200km of the study site
• Are in good physical health
• Are proficient in speaking and reading English
• Are willing to have all visits audio and video recorded
• Are able to swallow pills
• Agree to all study rules and commit to all medical and therapy visits
• If in psychotherapy, are willing to allow the study therapists to communicate directly with your therapist
• Are willing to stop taking psychiatric medications, herbal supplements, prescription and nonprescription medications during the study
• Agree not to drive for at least 24 hours after taking MDMA
• Agree to stay overnight on two separate occasions after each full-day MDMA-Assisted Psychotherapy Session
• Are not pregnant and will commit to not becoming pregnant during the study, if you are able to become pregnant
• Have a supportive relative, spouse, close friend or other caregiver who can serve as your emergency contact
• Agree to inform the researchers within 48 hours of any medical conditions and procedures

You may not qualify if:

• Are pregnant or could become pregnant and not using birth control
• Have a history of, or a current psychotic disorder, bipolar 1 disorder or dissociative identity disorder
• Have a history of a medical condition that could make receiving MDMA unsafe (e.g. glaucoma, heart attack, stroke, aneurysm)
• Have a history of Diabetes Mellitus (Type 2) that a doctor determines is not stable
• Have hypothyroidism (low activity in the thyroid gland) and are not on thyroid replacement
• Have high blood pressure, a history of heart disease, heart failure, irregular activity in the heart or require heart medication
• Have liver disease with symptoms
• Have history of hyponatremia (when you have decreased levels of sodium in the blood, which can cause confusion, seizures, fatigue and low levels of consciousness)
• Have history of hyperthermia (when you have a dangerously overheated body, usually in response to hot, humid weather)
• Weigh less than 48 kg
• Have recently engaged in suicidal behavior or had serious suicidal thoughts (this will be assessed by a therapist)
• Require ongoing therapy with a psychiatric medication
• Have a current eating disorder with active purging
• Have current major depressive disorder with psychotic features
• Are a serious risk to others

Sponsors & Collaborators

• Remedy: lead
• Multidisciplinary Association for Psychedelic Studies: collaborator

Study Sites (1)

Remedy Institute

Toronto, Ontario, M6G 1L5, Canada

Location

MeSH Terms

Conditions

Stress Disorders, Post-Traumatic

Interventions

N-Methyl-3,4-methylenedioxyamphetamine

Condition Hierarchy (Ancestors)

Stress Disorders, Traumatic; Trauma and Stressor Related Disorders; Mental Disorders

Intervention Hierarchy (Ancestors)

Amphetamines; Phenethylamines; Ethylamines; Amines; Organic Chemicals

Study Officials

• Alison Bruni, MD

  Remedy Institute

  PRINCIPAL INVESTIGATOR

• Anne Wagner, PhD

  Remedy Institute

  STUDY CHAIR

Study Design

• Study Type: interventional
• Phase: phase 2
• Allocation: NA
• Masking: NONE
• Purpose: TREATMENT
• Intervention Model: SINGLE GROUP
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 19, 2021
• First Posted: October 5, 2021
• Study Start: October 4, 2021
• Primary Completion: November 1, 2024
• Study Completion: November 1, 2024
• Last Updated: November 14, 2024

Record last verified: 2024-11

Data Sharing

• IPD Sharing: Will not share

Locations

CA (1)